Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Igenomix US and announce a new collaboration.

Igenomix US
Posted on: 31 Oct 17

MIAMI, Oct. 30, 2017 /PRNewswire/ -- Igenomix US, part of one of the world-leading reproductive genetics companies, is pleased to announce its new collaboration with, creator of eIVF, one of the largest and only web enabled, fully-customizable software systems specific to the IVF community.  This collaboration will allow unprecedented access and ease of ordering/receiving test results to the more than 130 IVF centers who currently use eIVF in their practice.

This new collaboration between Igenomix and Practice Highway's eIVF product will allow for one click ordering of any test on the Igenomix test menu, and will deliver test results directly into the patient's chart.  This direct access and thorough integration in eIVF completely eliminates installation and implementation of individual interfaces for each practice.  This new system will also ease the consenting process for both parties making it even easier to speak to patients about genetic testing.

Igenomix provides genetic services to fertility centers across the United States and Canada encompassing all phases of fertility treatment, specifically in preimplantation genetic screening (PGS), preimplantation genetic diagnosis (PGD), product of conceptions (POC) and its patented endometrial receptivity assay (ERA).  Each of these tests has helped hundreds of thousands of couples around the world to conceive healthy children by genetically testing both the embryo and the endometrium to ensure optimal embryo transfer timing with the best possible embryos.  Igenomix US, headquartered in Miami, FL, with labs also in Jersey City, NJ, Torrance, CA and Montreal, uses high resolution, next generation sequencing (NGS) for all its testing platforms and incorporates the latest in robotic technology to reduce the risk of mistakes and create much more reproducible results across all platforms and tests.   

"This project is a priority initiative in our strategy to increase the value that we provide to the clinics and their patients. Connecting our lab information system with eIVF is a big step toward achieving this goal in the US.  We look forward to further development and collaboration between Igenomix and," said David Jimenez, CEO of Igenomix.

"We are excited to work with Igenomix and what the future holds," noted PracticeHwy Founder, Jawid Rahimi.

About ( is a privately held healthcare software company based in Dallas, Texas.  The company was founded as a result of failure to force-fit a traditional EMR product in a Reproductive Science setting. In October 2002, after a long period of beta testing at Boston IVF, PracticeHwy launched its first version of eIVF for general release.  It was, and still continues to be, the only web enabled, fully customizable software system dedicated to REI practices. PracticeHwy is knowns for its continuous pursuit of excellence in the Fertility industry by providing the most powerful, yet efficient, software system for fertility clinics across the World. Currently approximately 130 practices and clinics utilize eIVF.  The Company continues to experience significant growth – in spite of never having an external sales force.  eIVF's portal based system provides quick access, streamlined processes and data consolidation to all aspects of a fertility clinic's operation. eIVF and its physician partners have access to cycle data on over 350,000 patients and nearly 700,000 cycles.

About Igenomix
Igenomix ( was created in 2011.  Today it is one of the world's leading providers of advanced services in reproductive genetics, operating from eleven laboratories worldwide.  Its constant efforts in R&D, led by Prof. Dr. Carlos Simón, enable Igenomix to create and develop specific tools to support professionals in the reproductive medicine field.  Specialist services offered include PGS (Pre-Implantation Genetic Screening), NACE (Non-invasive Prenatal Test); CGT (Carrier Genetic Test); PGD (Preimplantation Genetic Diagnosis) and ERA (Endometrial Receptivity Assay).


Editor's Details

Mike Wood

Last updated on: 31/10/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.